$GLSI News

Last published 3mo ago

3mo agoGLSIGreenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027GlobeNewswireSTAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
3mo agoGLSIGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United KingdomGlobeNewswireSTAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
3mo agoGLSIGreenwich LifeSciences Provides Clinical Updates on FLAMINGO-01GlobeNewswireSTAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
3mo agoGLSIGreenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01GlobeNewswireSTAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
4mo agoGLSIGreenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01GlobeNewswireSTAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
5mo agoGLSIGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026GlobeNewswireSTAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
5mo agoGLSIGreenwich LifeSciences Provides Update Regarding Form 10-K FilingGlobeNewswireSTAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
5mo agoGLSIGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingGlobeNewswireSTAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical
6mo agoGLSIGreenwich LifeSciences Provides Update Regarding Form 10-K FilingGlobeNewswireSTAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
6mo agoGLSIGreenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026GlobeNewswireSTAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
6mo agoGLSIGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingGlobeNewswireSTAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
6mo agoGLSIGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026GlobeNewswireSTAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
7mo agoGLSIGreenwich LifeSciences Provides Update on Financing StrategyGlobeNewswireSTAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
7mo agoGLSIGreenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market PotentialGlobeNewswireSTAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
8mo agoGLSIGreenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01GlobeNewswireSTAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
8mo agoGLSIGreenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01GlobeNewswireSTAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
8mo agoGLSIGreenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026GlobeNewswireSTAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
9mo agoONCY ABBV GMAB ADCT+1$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command PremiumPR NewswireThe oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This...
9mo agoGLSIGreenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing StrategyGlobeNewswireSTAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
9mo agoGLSIGreenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01GlobeNewswireSTAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
10mo agoONCY BCTX GLSI CTOR+1How $594B in Precision Tech is Cracking the Metastatic Cancer CodePR NewswireThe global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace traditional chemotherapy[1]....
10mo agoGLSIGreenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026GlobeNewswireSTAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
11mo agoGLSIGreenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01GlobeNewswireSTAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
11mo agoGLSIGreenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01GlobeNewswireSTAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
11mo agoGLSIGreenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to DateGlobeNewswireSTAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical TrialGlobeNewswireSTAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to BelgiumGlobeNewswireSTAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical TrialGlobeNewswireSTAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to IrelandGlobeNewswireSTAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences' GLSI-100 Granted US FDA Fast Track DesignationGlobeNewswireSTAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSINoble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciencesGlobeNewswireSTAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations TeamGlobeNewswireSTAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Expansion of Flamingo-01 into RomaniaGlobeNewswireSTAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Provides Update on CEO Interviews & Corporate EventsGlobeNewswireSTAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy
1y agoGLSIGreenwich LifeSciences Provides Global Update on FLAMINGO-01GlobeNewswireSTAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical TrialGlobeNewswireSTAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026GlobeNewswireSTAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01GlobeNewswireSTAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01GlobeNewswireSTAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in EuropeGlobeNewswireSTAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Activation of Flamingo-01 in PolandGlobeNewswireSTAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01GlobeNewswireSTAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Provides Update on Commercial ManufacturingGlobeNewswireSTAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01GlobeNewswireSTAFFORD, Texas, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into FranceGlobeNewswireSTAFFORD, Texas, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Partners with GIM in ItalyGlobeNewswireSTAFFORD, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
1y agoGLSIGreenwich LifeSciences Provides Update on Corporate EventsGlobeNewswireSTAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy
2y agoGLSIGreenwich LifeSciences Provides Update on Expansion of Flamingo-01 into SpainGlobeNewswireSTAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
2y agoGLSIGreenwich LifeSciences Set to Join Russell 2000 Index AgainGlobeNewswireSTAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
2y agoGLSIGreenwich LifeSciences Announces $2.5 Million Private PlacementGlobeNewswireSTAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical